Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on October 18, 2018. The registrant is a Delaware corporation headquartered in San Diego, CA. The filing reports a current event regarding an upcoming update on the company's clinical program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain financial statements or performance metrics.
Material Changes
There are no material financial changes reported in this document. The primary event is the announcement of a scheduled live conference call and webcast on October 24, 2018, at 8:30 am EDT to provide an update on the Onvansertib clinical program.
Guidance, Outlook, and Risks
Management has indicated an upcoming communication regarding the Onvansertib clinical program. The filing does not contain specific financial guidance, risk factors, or details on contingencies beyond the scheduled update. The press release detailing the update is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the company name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the date and time of the Onvansertib clinical program update (October 24, 2018, 8:30 am EDT).
- Review the attached press release (Exhibit 99.1) for specific clinical data or trial results.
- Note that no financial data is included in this specific 8-K filing.